Coverage / LON:FARN / Trade Card

LON:FARN

Faron Pharmaceuticals Oy

OPPORTUNISTIC BUY Analysis generated 2026-10-28 Market data as of 2026-11-13 Market data 2 days old 28.00p Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
28.00p
Buy <=wait / entry
20.33p
Trim >=take some off
45.00p
Thesis breakThe investment thesis would be invalidated by a definitive failure of bexmarilim...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Strengthened balance sheet with EUR 32.0M cash supporting advancement into randomized Phase 2b trial in higher-risk MDS
  • Positive FDA EOP2 meeting feedback and orphan drug designations for bexmarilimab in HR-MDS
  • BEXMAB Phase I/II efficacy results presented at ASCO, EHA, ESMO and ASH congresses
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n